Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis

References

• Ljungberg B, Campbell SC, Cho HY, Jacqmin D, Lee JE, Weikert S, Kiemeney LA. The epidemiology of renal cell carcinoma. Eur Urol 2011; 60:615-21; PMID:21741761; http://dx.doi.org/10.1016/j.eururo.2011.06.049
   PubMed Web of Science ®Google Scholar
• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49:1374-403; PMID: 23485231; http://dx.doi.org/10.1016/j.ejca.2012.12.027
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010; 58:398-406; PMID:20633979; http://dx.doi.org/10.1016/j.eururo.2010.06.032
   PubMed Web of Science ®Google Scholar
• Geiger C, Nössner E, Frankenberger B, Falk CS, Pohla H, Schendel DJ. Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma. J Mol Med 2009; 87:595-612; PMID:19271159; http://dx.doi.org/10.1007/s00109-009-0455-2
   PubMedGoogle Scholar
• Schleypen JS, Von Geldern M, Weiss EH, Kotzias N, Rohrmann K, Schendel DJ, Falk CS, Pohla H. Renal cell carcinoma-infiltrating natural killer cells express different repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes. Int J Cancer 2003; 106:905-12; PMID:12918068; http://dx.doi.org/10.1002/ijc.11321
   PubMed Web of Science ®Google Scholar
• Schleypen JS, Baur N, Kammerer R, Nelson PJ, Rohrmann K, Gröne EF, Hohenfellner M, Haferkamp A, Pohla H, Schendel DJ, et al. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res 2006; 12:718-25; PMID:16467081; http://dx.doi.org/10.1158/1078-0432.CCR-05-0857
   PubMed Web of Science ®Google Scholar
• Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean MC, Riquet M, Crozet L, Ouakrim H, Goc J, Cazes A, et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res 2013; 19:4079-91; PMID:23785047; http://dx.doi.org/10.1158/1078-0432.CCR-12-3847
   PubMed Web of Science ®Google Scholar
• Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H, Ohtani H. Proliferative activity of intratumoral CD8+ T lymphocytes as a prognostic factor in human renal cell carcinoma: Clinicopathologic demonstration of antitumor immunity. Cancer Res 2001; 61:5132-6; PMID:11431351
   PubMed Web of Science ®Google Scholar
• Hotta K, Sho M, Fujimoto K, Shimada K, Yamato I, Anai S, Konishi N, Hirao Y, Nonomura K, Nakajima Y. Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma. Br J Cancer 2011; 105:1191-6; PMID:21934683; http://dx.doi.org/10.1038/bjc.2011.368
   PubMed Web of Science ®Google Scholar
• Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449: 419-26; PMID:17898760; http://dx.doi.org/10.1038/nature06175
   PubMed Web of Science ®Google Scholar
• Moretta A. The dialogue between human natural killer cells and dendritic cells. Curr Opin Immunol 2005; 17:306-11; PMID:15886122; http://dx.doi.org/10.1016/j.coi.2005.03.004
   PubMed Web of Science ®Google Scholar
• Wehner R, Dietze K, Bachmann M, Schmitz M. The bidirectional crosstalk between human dendritic cells and natural killer cells. J Innate Immun 2011; 3:258-63; PMID:21411969; http://dx.doi.org/10.1159/000323923
   PubMedGoogle Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258
   PubMed Web of Science ®Google Scholar
• Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995; 1:1297-302; PMID:7489412; http://dx.doi.org/10.1038/nm1295-1297
   PubMed Web of Science ®Google Scholar
• Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Vieweg J, Gilboa E. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000; 6:1011-7; PMID:10973321; http://dx.doi.org/10.1038/79519
   PubMed Web of Science ®Google Scholar
• Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4:328-32; PMID:9500607; http://dx.doi.org/10.1038/nm0398-328
   PubMed Web of Science ®Google Scholar
• Wierecky J, Müller MR, Wirths S, Halder-Oehler E, Dörfel D, Schmidt SM, Häntschel M, Brugger W, Schröder S, Horger MS, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006; 66:5910-8; PMID:16740731; http://dx.doi.org/10.1158/0008-5472.CAN-05-3905
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistent prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
   PubMed Web of Science ®Google Scholar
• Schäkel K, Mayer E, Federle C, Schmitz M, Riethmüller G, Rieber EP. A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur J Immunol 1998; 28:4084-93; PMID:9862344; http://dx.doi.org/10.1002/(SICI)1521-4141(199812)28:12%3c4084::AID-IMMU4084%3e3.0.CO;2-4
   PubMed Web of Science ®Google Scholar
• Schäkel K, Kannagi R, Kniep B, Goto Y, Mitsuoka C, Zwirner J, Soruri A, von Kietzell M, Rieber EP. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity 2002; 17:289-301; PMID:12354382; http://dx.doi.org/10.1016/S1074-7613(02)00393-X
   PubMed Web of Science ®Google Scholar
• Schäkel K, von Kietzell M, Hänsel A, Ebling A, Schulze L, Haase M, Semmler C, Sarfati M, Barclay AN, Randolph GJ, et al. Human 6-sulfo LacNAc-expressing dendritic cells are principal producers of early interleukin-12 and are controlled by erythrocytes. Immunity 2006; 24:767-77; PMID:16782032; http://dx.doi.org/10.1016/j.immuni.2006.03.020
   PubMed Web of Science ®Google Scholar
• Hänsel A, Günther C, Ingwersen J, Starke J, Schmitz M, Bachmann M, Meurer M, Rieber EP, Schäkel K. Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong Th17/Th1 T-cell responses. J Allergy Clin Immunol 2011; 127:787-94; PMID:21377044; http://dx.doi.org/10.1016/j.jaci.2010.12.009
   PubMed Web of Science ®Google Scholar
• Döbel T, Kunze A, Babatz J, Tränkner K, Ludwig A, Schmitz M, Enk AH, Schäkel K. FcgRIII equips immature 6-sulfo LacNAc-expressing dendritic cells (slanDCs) with a unique capacity to handle IgG-complexed antigens. Blood 2013; 121:3609-18; PMID:23460612; http://dx.doi.org/10.1182/blood-2012-08-447045
   PubMed Web of Science ®Google Scholar
• Schmitz M, Zhao S, Schäkel K, Bornhäuser M, Ockert D, Rieber EP. Native human blood dendritic cells as potent effectors in antibody-dependent cellular cytotoxicity. Blood 2002; 100:1502-4; PMID:12149240; http://dx.doi.org/10.1182/blood-2001-12-0304
   PubMedGoogle Scholar
• Schmitz M, Zhao S, Deuse Y, Schäkel K, Wehner R, Wöhner H, Hölig K, Wienforth F, Kiessling A, Bornhäuser M, et al. Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity. J Immunol 2005; 174:4127-34; PMID:15778372; http://dx.doi.org/10.4049/jimmunol.174.7.4127
   PubMed Web of Science ®Google Scholar
• Wehner R, Löbel B, Bornhäuser M, Schäkel K, Cartellieri M, Bachmann M, Rieber EP, Schmitz M. Reciprocal activating interaction between 6-sulfo LacNAc(+) dendritic cells and NK cells. Int J Cancer 2009; 124:358-66; PMID:18942710; http://dx.doi.org/10.1002/ijc.23962
   PubMedGoogle Scholar
• Hänsel A, Günther C, Baran W, Bidier M, Lorenz HM, Schmitz M, Bachmann M, Döbel T, Enk AH, Schäkel K. Human 6-sulfo LacNAc (slan) dendritic cells have molecular and functional features of an important pro-inflammatory cell type in lupus erythematosus. J Autoimmun 2013; 40:1-8; PMID:22890025; http://dx.doi.org/10.1016/j.jaut.2012.07.005
   PubMed Web of Science ®Google Scholar
• Vermi W, Micheletti A, Lonardi S, Costantini C, Calzetti F, Nascimbeni R, Bugatti M, Codazzi M, Pinter PC, Schäkel K, et al. slanDCs selectively accumulate in carcinoma-draining lymph nodes and marginate metastatic cells. Nat Commun 2014; 5:3029; PMID:24398631; http://dx.doi.org/10.1038/ncomms4029
   PubMed Web of Science ®Google Scholar
• Vermi W, Lonardi S, Bugatti M, Calzetti F, Micheletti A, Cassatella MA. slanDCs in carcinoma-draining lymph nodes. Oncoimmunology 2014; 3:e28246; PMID:24843832
   PubMedGoogle Scholar
• Manavalan JS, Rossi PC, Vlad G, Piazza F, Yarilina A, Cortesini R, Mancini D, Suciu-Foca N. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol 2003; 11:245-58; PMID:12967778; http://dx.doi.org/10.1016/S0966-3274(03)00058-3
   PubMed Web of Science ®Google Scholar
• Seliger B, Fedorushchenko A, Brenner W, Ackermann A, Atkins D, Hanash S, Lichtenfels R. Ubiquitin COOH-terminal hydrolase 1: a biomarker of renal cell carcinoma associated with enhanced tumor cell proliferation and migration. Clin Cancer Res 2007; 13:27-37; PMID:17200335; http://dx.doi.org/10.1158/1078-0432.CCR-06-0824
   PubMed Web of Science ®Google Scholar
• Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008; 8:467-77; PMID:18500231; http://dx.doi.org/10.1038/nri2326
   PubMed Web of Science ®Google Scholar
• Seliger B, Quandt D. The expression, function, and clinical relevance of B7 family members in cancer. Cancer Immunol Immunother 2012; 61:1327-41; PMID:22695874; http://dx.doi.org/10.1007/s00262-012-1293-6
   PubMed Web of Science ®Google Scholar
• Thurnher M, Radmayr C, Ramoner R, Ebner S, Böck G, Klocker H, Romani N, Bartsch G. Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer 1996; 68:1-7; PMID:8895531; http://dx.doi.org/10.1002/(SICI)1097-0215(19960927)68:1%3c1::AID-IJC1%3e3.0.CO;2-V
   PubMed Web of Science ®Google Scholar
• Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res 1998; 4:585-93; PMID:9533525
   PubMed Web of Science ®Google Scholar
• Middel P, Brauneck S, Meyer W, Radzun HJ. Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma. BMC Cancer 2010; 10:578; PMID:20969772; http://dx.doi.org/10.1186/1471-2407-10-578
   PubMed Web of Science ®Google Scholar
• Figel AM, Brech D, Prinz PU, Lettenmeyer UK, Eckl J, Turqueti-Neves A, Mysliwietz J, Anz D, Rieth N, Muenchmeier N, et al. Human renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations. Am J Pathol 2011; 179:436-51; PMID:21703422; http://dx.doi.org/10.1016/j.ajpath.2011.03.011
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454:436-44; PMID:18650914; http://dx.doi.org/10.1038/nature07205
   PubMed Web of Science ®Google Scholar
• Disis ML. Immune regulation of Cancer. J Clin Oncol 2010; 28:4531-8; PMID:20516428; http://dx.doi.org/10.1200/JCO.2009.27.2146
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245
   PubMed Web of Science ®Google Scholar
• Giraldo NA, Becht E, Remark R, Damotte D, Sautès-Fridman C, Fridman WH. The immune contexture of primary and metastatic human tumours. Curr Opin Immunol 2014; 27:8-15; PMID:24487185; http://dx.doi.org/10.1016/j.coi.2014.01.001
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
   PubMed Web of Science ®Google Scholar
• Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009; 27:5944-51; PMID:19858404; http://dx.doi.org/10.1200/JCO.2008.19.6147
   PubMed Web of Science ®Google Scholar
• Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141:39-51; PMID:20371344; http://dx.doi.org/10.1016/j.cell.2010.03.014
   PubMed Web of Science ®Google Scholar
• Vicari AP, Caux C, Trinchieri G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 2002; 12:33-42; PMID:11926410; http://dx.doi.org/10.1006/scbi.2001.0400
   PubMed Web of Science ®Google Scholar
• Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5:263-74; PMID:15776005; http://dx.doi.org/10.1038/nrc1586
   PubMed Web of Science ®Google Scholar
• Ma Y, Aymeric L, Locher C, Kroemer G, Zitvogel L. The dendritic cell-tumor cross talk in cancer. Curr Opin Immunol 2011; 23:146-52; PMID:20970973; http://dx.doi.org/10.1016/j.coi.2010.09.008
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2:1096-103; PMID:8837607; http://dx.doi.org/10.1038/nm1096-1096
   PubMed Web of Science ®Google Scholar
• Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C, Blay JY. Inhibition of differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998; 92:4778-91; PMID:9845545
   PubMed Web of Science ®Google Scholar
• Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T, Wei S, Krzysiek R, Durand-Gasselin I, Gordon A, et al. Stromal-derived factor-1 in human tumors recruits and alters function of plamacytoid precursor dendritic cells. Nat Med 2001; 7:1339-46; PMID:11726975; http://dx.doi.org/10.1038/nm1201-1339
   PubMed Web of Science ®Google Scholar
• Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6:655-63; PMID:7180965; http://dx.doi.org/10.1097/00000478-198210000-00007
   PubMed Web of Science ®Google Scholar
• Sobin LH, Gospodarowicz MK, Wittekind C, eds. Classification of malignant tumors. Oxford, UK: Wiley-Blackwell; 2009.
   Google Scholar